227 223

Cited 7 times in

Preoperative Volume-Based PET Parameter, MTV2.5, as a Potential Surrogate Marker for Tumor Biology and Recurrence in Resected Pancreatic Cancer

DC FieldValueLanguage
dc.contributor.author강창무-
dc.contributor.author윤미진-
dc.contributor.author이성환-
dc.contributor.author이우정-
dc.contributor.author황호경-
dc.date.accessioned2017-02-24T11:13:39Z-
dc.date.available2017-02-24T11:13:39Z-
dc.date.issued2016-
dc.identifier.issn0025-7974-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/146699-
dc.description.abstractThis study aims to evaluate the role of volume-based positron emission tomography parameters as potential surrogate markers for tumor recurrence in resected pancreatic cancer. Between January 2008 and October 2012, medical records of patients who underwent surgical resection for pancreatic ductal adenocarcinoma and completed ¹⁸F-fluorodeoxyglucose positron emission tomography/CT as a part of preoperative staging work-up were retrospectively reviewed. Not only clinicopathologic variables but also positron emission tomography parameters such as SUVmax, MTV2.5 (metabolic tumor volume), and TLG (total lesion glycolysis) were obtained. Twenty-six patients were women and 31 were men with a mean age of 62.9 ± 9.1 years. All patients were preoperatively determined to resectable pancreatic cancer except 1 case with borderline resectability. R0 resection was achieved in all patients and 45 patients (78.9%) received postoperative adjuvant chemotherapy with or without radiation therapy. Median overall disease-free survival was 12.8 months with a median overall disease-specific survival of 25.1 months. SUVmax did not correlate with radiologic tumor size (P = 0.501); however, MTV2.5 (P = 0.001) and TLG (P = 0.009) were significantly associated with radiologic tumor size. In addition, MTV2.5 (P < 0.001) and TLG (P < 0.001) were significantly correlated with a tumor differentiation. There were no significant differences in TLG and SUVmax according to lymph node ratio; only MTV2.5 was related to lymph node ratio with marginal significance (P = 0.055). In multivariate analysis, lymph node ratio (Exp [β] = 2.425, P = 0.025) and MTV2.5 (Exp[β] = 2.273, P = 0.034) were identified as independent predictors of tumor recurrence following margin-negative resection. Even after tumor size-matched analysis, MTV2.5 was still identified as significant prognostic factor in resected pancreatic cancer (P < 0.05). However, preoperative neoadjuvant treatment attenuated adverse oncologic impact of high preoperative MTV2.5 (P = 0.210). Preoperatively determined volume-based PET parameter, MTV2.5, can potentially be used as a surrogate marker to estimate tumor biology and tumor recurrence. Individual treatment strategies for pancreatic cancer can be suggested based on patients' preoperative MTV2.5.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherLippincott Williams & Wilkins-
dc.relation.isPartOfMedicine-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAged-
dc.subject.MESHCarcinoma, Pancreatic Ductal*/pathology-
dc.subject.MESHCarcinoma, Pancreatic Ductal*/surgery-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHFluorodeoxyglucose F18/pharmacology*-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoadjuvant Therapy/methods-
dc.subject.MESHNeoadjuvant Therapy/statistics & numerical data-
dc.subject.MESHNeoplasm Recurrence, Local*-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHPancreatectomy*/adverse effects-
dc.subject.MESHPancreatectomy*/methods-
dc.subject.MESHPancreatic Neoplasms*/pathology-
dc.subject.MESHPancreatic Neoplasms*/surgery-
dc.subject.MESHPositron-Emission Tomography*/methods-
dc.subject.MESHPositron-Emission Tomography*/statistics & numerical data-
dc.subject.MESHPredictive Value of Tests-
dc.subject.MESHPreoperative Care*/methods-
dc.subject.MESHPreoperative Care*/statistics & numerical data-
dc.subject.MESHPrognosis-
dc.subject.MESHRadiopharmaceuticals/pharmacology-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHTumor Burden*-
dc.titlePreoperative Volume-Based PET Parameter, MTV2.5, as a Potential Surrogate Marker for Tumor Biology and Recurrence in Resected Pancreatic Cancer-
dc.typeArticle-
dc.publisher.locationUnited States-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Surgery-
dc.contributor.googleauthorChang Moo Kang-
dc.contributor.googleauthorSung Hwan Lee-
dc.contributor.googleauthorHo Kyoung Hwang-
dc.contributor.googleauthorMijin Yun-
dc.contributor.googleauthorWoo Jung Lee-
dc.identifier.doi10.1097/MD.0000000000002595-
dc.contributor.localIdA00088-
dc.contributor.localIdA02550-
dc.contributor.localIdA02875-
dc.contributor.localIdA02993-
dc.contributor.localIdA04497-
dc.relation.journalcodeJ02214-
dc.identifier.pmid26945350-
dc.contributor.alternativeNameKang, Chang Moo-
dc.contributor.alternativeNameYun, Mi Jin-
dc.contributor.alternativeNameLee, Sung Hwan-
dc.contributor.alternativeNameLee, Woo Jung-
dc.contributor.alternativeNameHwang, Ho Kyoung-
dc.contributor.affiliatedAuthorKang, Chang Moo-
dc.contributor.affiliatedAuthorYun, Mi Jin-
dc.contributor.affiliatedAuthorLee, Sung Hwan-
dc.contributor.affiliatedAuthorLee, Woo Jung-
dc.contributor.affiliatedAuthorHwang, Ho Kyoung-
dc.citation.volume95-
dc.citation.number9-
dc.citation.startPage2595-
dc.identifier.bibliographicCitationMedicine, Vol.95(9) : 2595, 2016-
dc.date.modified2017-02-24-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Nuclear Medicine (핵의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.